GoodRx Reports Q1 Revenue Decline and 89% Net Income Drop, but Raises Full-Year Guidance
GDRX sits 44% above its 52-week low of $1.77.
Summary
GoodRx reported a 4% revenue decrease and an 89.4% net income drop in Q1 2026, driven by declines in prescription transactions, but saw strong growth in Pharma Direct and subscriptions, leading management to raise its full-year 2026 guidance.
Key Events · Earnings and Guidance · GDRX
-
Q1 2026 Financial Performance
Total revenue decreased 4% year-over-year to $194.0 million, and net income fell 89.4% to $1.2 million, primarily due to a significant downturn in the core prescription transactions business.
-
Segment Performance Divergence
Prescription transactions revenue declined 24% to $113.7 million, while Pharma Direct revenue surged 82% to $52.2 million and subscription revenue increased 16% to $24.4 million.
-
Full-Year 2026 Guidance Raised
Management raised its full-year revenue guidance to $765-$785 million and Adjusted EBITDA expectations to over $235 million, indicating improved outlook despite Q1 results.
-
Share Repurchase Activity
The company repurchased 5.5 million shares of Class A common stock for an aggregate of $12.6 million during the first quarter, with $60.2 million remaining under its authorization.
Analysis · GDRX · Technology
GoodRx Holdings reported a challenging first quarter for 2026, with total revenue decreasing 4% year-over-year to $194.0 million and net income plummeting 89.4% to $1.2 million. The core prescription transactions revenue saw a significant 24% decline, attributed to broader changes in the retail pharmacy landscape and lower unit economics. However, the company demonstrated strong growth in its Pharma Direct segment, which surged 82% to $52.2 million, and subscription revenue, which increased 16% to $24.4 million. Despite the Q1 declines, management raised its full-year 2026 revenue guidance to $765-$785 million and Adjusted EBITDA expectations to over $235 million, signaling improved confidence in future performance relative to prior internal forecasts. The company also repurchased 5.5 million shares for $12.6 million during the quarter, reflecting its commitment to capital allocation priorities.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, GDRX was trading at $2.54 on NASDAQ in the Technology sector, with a market capitalization of approximately $880.4M. The 52-week trading range was $1.77 to $5.81. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.